1 Jaffe E, Harris N, Stein H, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues[M]. Lyon: IARC Press, 2001: 171-175.
3 Thompson MP, Kurzrock R. Epstein-Barr virus and cancer[J]. Clin Cancer Res, 2004, 10(3): 803-821.
[4]
4 Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma[J]. Lancet, 1964, 283(7335): 702-703.
[5]
5 Swerdllow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. Lyon: IARC Press, 2008.
[6]
6 Oyama T, Ichimura K, Suzuki R, et al. Senile EBV+B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients[J]. Am J Surg Pathol, 2003, 27(1): 16-26.
[7]
7 Ok CY, Papathomas TG, Medeiros L. EBV-positive diffuse large B-cell lymphoma of the elderly[J]. Blood, 2013, 122(3): 328-340.
[8]
8 Hoeller S, Tzankov A, Pileri SA, et al. Epstein-Barr virus positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations[J]. Hum Pathol, 2010, 41(3): 352-357.
[9]
9 Castillo JJ, Beltran BE, Miranda RN, et al. Epstein-Barr virus-positive diffuse large B-Cell lymphoma of the elderly: what we know so far[J]. Oncologist, 2011, 16(1): 87-96.
[10]
10 Montes-Moreno S, Odqvist L, Diaz-Perez JA, et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation[J]. Mod Pathol, 2012, 25(7): 968-982.
[11]
11 Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma[J]. Blood, 2007, 110(3): 972-978.
[12]
12 Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-Cell lymphoma and mantle cell lymphoma[J]. J Clin Oncol, 2011, 29(6): 690-697.
[13]
13 Barreto L, Azambuja D, De Morais JC. Expression of immunohistochemical markers in patients with AIDS-related lymphoma[J]. Braz J Infect Dis, 2012, 16(1): 74-77.
[14]
14 Chao C, Silverberg MJ, Martinez-Maza OA, et al. Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell lymphoma[J]. Clin Cancer Res, 2012, 18(17): 4702-4712.
[15]
15 Tumwine LK, Orem J, Kerchan P, et al. Research article EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda[J]. Infect Agent Cancer, 2010, 5: 12.
[16]
16 Matthews GV, Bower M, Mandalia S, et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy[J]. Blood, 2000, 96(8): 2730-2734.
[17]
17 Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma[J]. Blood, 2012, 119(14): 3245-3255.
[18]
18 Kaplan LD. HIV-associated lymphoma[J]. Best Pract Res Clin Haematol, 2012, 25(1): 101-117.
[19]
19 Dalia S, Chavez J, Castillo JJ, et al. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies[J]. Leuk Res, 2013, 37(9): 1107-1115.
[20]
20 Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study[J]. Lancet Oncol, 2010, 11(9): 827-834.
[21]
21 Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European Multicenter Case-Control Study EPILYMPH[J]. Gastroenterology, 2006, 131(6): 1879-1886.
[22]
22 Visco C, Arcaini L, Brusamolino E, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy[J]. Ann Oncol, 2006, 17(9): 1434-1440.
[23]
23 Xie WZ, Zhou D, Hu KY, et al. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy[J]. Exp Ther Med, 2013, 6(1): 109-114.
[24]
24 Chen XQ, Peng JW, Lin GN, et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy[J]. Med Oncol, 2012, 29(2): 1237-1241.
[25]
25 Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis[J]. Blood, 2010, 116(24): 5119-5125.
[26]
26 Nishikawa H, Tsudo M, Osaki Y. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience[J]. Oncol Rep, 2012, 28(3): 835-840.
[27]
27 Nooka A, Shenoy PJ, Sinha R, et al. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature[J]. Clin Lymphoma Myeloma Leuk, 2011, 11(5): 379-384.
[28]
28 Beltran BE, Quinones P, Morales D, et al. Diffuse large B-cell lymphoma in human T-lymphotropic virus type 1 carriers[J]. Leuk Res Treatment, 2012, 2012: 1-4.
